Sanofi (ETR:SNW)
Germany · Delayed Price · Currency is EUR | Market Cap | 101.41B |
| Revenue (ttm) | 45.74B |
| Net Income (ttm) | 9.13B |
| Shares Out | n/a |
| EPS (ttm) | 7.36 |
| PE Ratio | 11.11 |
| Forward PE | 10.38 |
| Dividend | 3.92 (4.70%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 12,566 |
| Average Volume | 11,328 |
| Open | 84.43 |
| Previous Close | 84.77 |
| Day's Range | 83.37 - 85.09 |
| 52-Week Range | 76.43 - 110.82 |
| Beta | 0.44 |
| RSI | 53.06 |
| Earnings Date | Oct 24, 2025 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial StatementsNews
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out
Shares of Apogee Therapeutics have gained 34% over the past two days as the small biotech looks to take on Regeneron and Sanofi.
Sanofi and Orano Med succeed in mid-stage trial for neuroendocrine tumor therapy
Sanofi (SNY) stock is in focus as its AlphaMedix therapy developed with Orano Med succeeds in a mid-stage trial for neuroendocrine tumors. Read more here.
BenchSci Announces Three-Year License Agreement with Sanofi to Access and Use BenchSci's ASCEND Platform
TORONTO--(BUSINESS WIRE)--BenchSci Announces Three-Year License Agreement with Sanofi to Access and Use BenchSci's ASCEND Platform.
Sanofi's AlphaMedix Shows Strong Phase 2 Results For Advanced Neuroendocrine Tumor Treatment
(RTTNews) - Sanofi SA (SNY, SNYNF, SAN.PA) announced promising results from its ALPHAMEDIX-02 Phase 2 clinical trial evaluating AlphaMedix (212Pb-DOTAMTATE), a novel somatostatin receptor-targeted alp...
Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
AlphaMedix TM ( 212 Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
Novavax (NVAX) Transfers EU Vaccine Rights to Sanofi for $25M
Novavax (NVAX) Transfers EU Vaccine Rights to Sanofi for $25M
Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU
Sanofi (SNY) Gains Full EU Control of Nuvaxovid from Novavax
Sanofi (SNY) Gains Full EU Control of Nuvaxovid from Novavax
AstraZeneca Taps Gene Editing And AI Platform For Drug Discovery For Immunology Diseases
Algen Biotechnologies , a privately held biotech company specializing in advanced CRISPR gene modulation and AI-driven drug discovery, has announced a multi-target partnership with AstraZeneca Plc (NA...
Sanofi: Undervalued 2026 Pipeline, And Solid Results (Rating Upgrade)
Bullish Two Hundred Day Moving Average Cross - SNY
In trading on Friday, shares of Sanofi (Symbol: SNY) crossed above their 200 day moving average of $50.89, changing hands as high as $51.05 per share. Sanofi shares are currently trading up about 1.7%...
Sanofi (SNY) Supports Revvity's Expansion in Type 1 Diabetes Assay
Sanofi (SNY) Supports Revvity's Expansion in Type 1 Diabetes Assay
Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with s...
Sanofi (SNY) Under EU Antitrust Investigation Over Vaccine Practices
Sanofi (SNY) Under EU Antitrust Investigation Over Vaccine Practices
Big pharma is at war with the UK, and the government can’t back down now | Nick Dearden
The industry has always wanted the NHS to pay more for its drugs; now it is pulling research and investment out of Britain This year so far, some of the biggest pharmaceutical corporations in the worl...
QuantHealth Secures Strategic Investment from Sanofi Ventures to Accelerate AI-Driven Clinical Trials
TEL AVIV, Isreal & CAMBRIDGE, Mass.--(BUSINESS WIRE)--QuantHealth, a pioneer in AI-driven clinical trial simulation, announced a strategic investment from Sanofi Ventures, the venture capital arm of g...
Novavax (NVAX) Expands License for Matrix-M with Sanofi
Novavax (NVAX) Expands License for Matrix-M with Sanofi
Novavax Expands Collaboration And License Agreement With Sanofi On Use Of Matrix-M Adjuvant
(RTTNews) - Novavax, Inc. (NVAX) announced Tuesday progress on its collaboration and license agreement (CLA) with Sanofi SA (SNY) regarding Novavax's Matrix-M adjuvant. The companies have amended thei...
Novavax allows Sanofi to use Matrix-M adjuvant for pandemic flu candidate
MoonLake Immunotherapeutics Stock Plummets After Phase 3 Data Readouts
MoonLake Immunotherapeutics ‘ (NASDAQ: MLTX) stock price fell off a cliff Monday after it reported week-16 results from its Phase 3 VELA-1 and VELA-2 trials . The trials used HiSCR75—a 75% reduction ...
Emma Walmsley To Step Down As GSK CEO After Nine Years, Luke Miels To Lead Starting January 2026
GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026. Luke will succeed the current CEO, Dame Emma Wal...
A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff
Novo Nordisk, Sanofi, and AstraZeneca face the largest dollar exposure to President Trump's new 100% tariff on imported branded drugs. NVO's heavy reliance on U.S. sales and imported GLP-1 products pu...
Sanofi Expands Insulin Savings Program To Cover All US Patients
The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA's (NASDAQ: S...
Sanofi Expands Insulin Savings Program To Cover All US Patients
The U.S. Food and Drug Administration removed the Risk Evaluation ... Full story available on Benzinga.com
Sanofi (SNY) Expands Affordable Insulin Access Program
Sanofi (SNY) Expands Affordable Insulin Access Program